Dehydroepiandrosterone (DHEA) Intervention To Treat Ovarian Aging

• Status: Completed
• Trial end date: 2014-12-01
• Target enrollment: 0
• Participant gender: Female

Summary

• To test the hypothesis that supplementation of DHEA for at least twelve weeks prior to and during ovarian stimulation increases oocyte quantity (number of oocytes retrieved) and oocyte quality (clinical pregnancy rates and molecular markers) following IVF and IVF/ICSI treatment.

• To evaluate the feasibility of conducting a large multicentre trial

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Nottingham
• Treatments: Dehydroepiandrosterone; Menotropins

Criteria

Inclusion Criteria:

• Women aged above 23 years with diminished ovarian reserve (predicted to be poor-responder), defined as antral follicle count <10 and/or Anti-Mullerian hormone <5pmol/L

• Women undergoing IVF and IVF/ICSI treatment

• Women must have a regular spontaneous menstrual cycle of 21 - 35 days

Exclusion Criteria:

• Women with BMI >35 Kg/M2

• Women with a single ovary

• Women with untreated hydrosalpinx/ submucous fibroid/ endometrial polyp at the start of treatment

• Women with any history of seizure disorders

• Women with previous participation in this trial in an earlier treatment cycle

• Women with any known endocrine disorders such as congenital adrenal hyperplasia, thyroid diseases, hyperprolactinemia

• Known allergy to DHEA

• Diabetic women on insulin as insulin lowers DHEA levels and might reduce the effectiveness of DHEA supplements.